Get the Stockscreener App
2.55
5.37%
0.13
After Hours:
2.49
-0.06
-2.35%
Ovid Therapeutics Inc stock is traded at $2.55, with a volume of 22.55M.
It is up +5.37% in the last 24 hours and up +4.08% over the past month.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
See More
Previous Close:
$2.42
Open:
$2.4
24h Volume:
22.55M
Relative Volume:
7.99
Market Cap:
$475.93M
Revenue:
$7.12M
Net Income/Loss:
$-24.17M
P/E Ratio:
-10.48
EPS:
-0.2434
Net Cash Flow:
$-41.95M
1W Performance:
+12.33%
1M Performance:
+4.08%
6M Performance:
+43.26%
1Y Performance:
+643.44%
1-Day Range:
$2.39
$2.60
1-Week Range:
$2.19
$2.60
52-Week Range:
$0.3001
$3.105
Ovid Therapeutics Inc Stock (OVID) Company Profile
Name
Ovid Therapeutics Inc
Sector
Industry
Phone
212-776-4381
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
2.55 | 475.93M | 7.12M | -24.17M | -41.95M | -0.2434 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Initiated | Roth Capital | Buy |
| Nov-17-25 | Initiated | Leerink Partners | Outperform |
| Oct-09-25 | Initiated | Oppenheimer | Outperform |
| Aug-08-25 | Resumed | B. Riley Securities | Buy |
| Jun-18-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-30-24 | Initiated | B. Riley Securities | Buy |
| Apr-29-24 | Initiated | H.C. Wainwright | Buy |
| Apr-05-24 | Initiated | Wedbush | Outperform |
| Dec-21-23 | Initiated | BTIG Research | Buy |
| Oct-13-23 | Initiated | Oppenheimer | Outperform |
| Apr-20-21 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-03-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-02-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-19 | Initiated | RBC Capital Mkts | Outperform |
| Apr-20-18 | Initiated | Ladenburg Thalmann | Buy |
View All
Ovid Therapeutics Inc Stock (OVID) Latest News
Ovid Therapeutics Inc (OVID) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ovid Therapeutics Inc. Actuals & Estimates (NASDAQ:OVID) - TradingView
OVID Forecast — Price Target — Prediction for 2027 - TradingView
AQST Stock Price and Chart — NASDAQ:AQST - TradingView
1OT Forecast — Price Target — Prediction for 2027 - TradingView
Ovid Therapeutics Inc. Actuals & Estimates (SWB:1OT) - TradingView
Price to earnings forward of Ovid Therapeutics Inc. – NASDAQ:OVID - TradingView
Ovid Therapeutics Inc (OVID) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy - Sahm
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to S&P Biotechnology Select Industry Index - marketscreener.com
Ovid Therapeutics (NASDAQ: OVID) grants director Anna Greka 130,000 stock options - Stock Titan
Ovid Therapeutics (OVID) director files initial Form 3 - Stock Titan
Ovid Therapeutics Inc (OVID) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ovid Therapeutics Inc (OVID) Institutional Confidence - TradingKey
Ovid Therapeutics Inc (OVID) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ovid Therapeutics Inc (OVID) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ovid Therapeutics Inc (OVID) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ovid Therapeutics Inc (OVID) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ovid Therapeutics Inc (OVID) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OVID: Multiple clinical milestones and strong financial runway position the pipeline for significant value creation - TradingView
Ovid Therapeutics Shareholders Back Board and Governance Proposals - The Globe and Mail
Ovid Therapeutics (OVID) Slips 1.97% as Shares Test Key Support LevelsStrong Buy Stocks - newsline.com
Ovid Therapeutics (NASDAQ: OVID) shareholders approve director, pay and auditor - Stock Titan
Ovid Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Ovid Board Move Puts Scientific Strategy Back In Focus - Kalkine Media
Ovid Therapeutics Expands Board, Appoints New Scientific Director - The Globe and Mail
Ovid Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Ovid Therapeutics appoints Anna Greka to board of directors - Investing.com UK
Ovid Therapeutics appoints Anna Greka to board of directors By Investing.com - Investing.com Canada
Anna Greka joins Ovid Therapeutics (NASDAQ: OVID) board, expanding it to seven - Stock Titan
Ovid Therapeutics Appoints Leading Physician-Scientist and - GlobeNewswire
OVIDOvid Therapeutics Inc Stock Price and Quote - Finviz
Ovid Therapeutics (OVID) Gains Nearly 4% as Shares Test Key ResistanceUnusual Put Volume - newsline.com
Will Ovid’s golden age of KCC2 metamorph CNS? - BioWorld News
H.C. Wainwright Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $4 - Moomoo
OVID SEC FilingsOvid Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Point72 (OVID) discloses shared 1.3% position, including warrants - Stock Titan
Eventide (OVID) discloses 12.8M-share, 7.3% position in Ovid Therapeutics - Stock Titan
Ovid Therapeutics (OVID) Schedule 13G: Sirenia/manager report 9.9% stake - Stock Titan
Balyasny group holds 5.33% of Ovid (NASDAQ: OVID) across funds - Stock Titan
Former Ovid CEO Dr. Jeremy Levin’s rallying cry for biotech - Pharma Voice
[SCHEDULE 13G/A] Ovid Therapeutics Inc. Amended Passive Investment Disclosure - Stock Titan
Jeremy Levin reports 4.5% stake in Ovid Therapeutics (NASDAQ: OVID) - Stock Titan
We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely - Yahoo Finance
Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $7 - Moomoo
LifeSci Capital Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5 - Moomoo
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com - Investing.com Australia
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target - Investing.com India
TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating - Moomoo
Ovid Therapeutics 1Q Research and Development Expenses $11.2M >OVID - Moomoo
William Blair Maintains Ovid Therapeutics(OVID.US) With Buy Rating - Moomoo
Ovid Therapeutics Inc Stock (OVID) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):